聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 21 分钟 32 秒 前

FDA Approves ZONTIVITY(TM) (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease

周一, 05/12/2014 - 15:19
ZONTIVITY Added to Standard of Care Demonstrated Long-Term Benefit Through Three Years WHITEHOUSE STATION, N.J.--(Healthcare Sales & Marketing Network)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. F...
Biopharmaceuticals, Cardiology, FDA
Merck, ZONTIVITY, vorapaxar

Allergan Board Unanimously Rejects Unsolicited Proposal from Valeant

周一, 05/12/2014 - 15:13
Valeant Proposal Substantially Undervalues Allergan and is Not in the Best Interests of Stockholders Allergan Expects to Increase EPS by 20 to 25 Percent in 2015 and by 20 Percent CAGR over Next Five Years IRVINE, Calif.--(Healthcare Sales & Marketi...
Biopharmaceuticals, Mergers & Acquisitions
Allergan, Valeant Pharmaceuticals

Akorn to Acquire VersaPharm for $440 Million

周五, 05/09/2014 - 15:51
Increases presence in the highly attractive niche dermatology market Adds $90 - 100 million in annual revenues Immediately accretive to earnings LAKE FOREST, Ill.--(Healthcare Sales & Marketing Network)--Akorn, Inc. (AKRX) today announced that it ...
Biopharmaceuticals, Generics, Mergers & Acquisitions
Akorn, VersaPharm

Prima BioMed's CVac(TM) Granted Fast Track Designation by FDA

周五, 05/09/2014 - 15:46
SYDNEY, AUSTRALIA--(Healthcare Sales & Marketing Network) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima") is pleased to announce today that the United States Food and Drug Administration ("FDA") granted Fast Track Designation to ...
Biopharmaceuticals, Oncology, FDA
Prima BioMed, CVac, ovarian cancer

Charleston Laboratories, Inc., Bolsters Senior Management Team

周四, 05/08/2014 - 13:34
JUPITER, Fla., May 8, 2014 -- (Healthcare Sales & Marketing Network) -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company focused on the research and development of novel pain products, today announced the company has appointed t...
Biopharmaceuticals, Personnel
Charleston Laboratories

Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors

周四, 05/08/2014 - 13:31
NEW YORK, May 8, 2014 -- (Healthcare Sales & Marketing Network) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, ...
Biopharmaceuticals, Personnel
Anavex Life Sciences

Neovasc Hires Industry Veteran Vicki Bebeau as Vice President, Clinical Affairs

周四, 05/08/2014 - 13:27
Bebeau Brings Her Extensive Experience in Managing Cardiac Device Clinical Programs to the Tiara™ and Neovasc Reducer™ New Product Programs New Clinical Initiatives for Tiara and the Neovasc Reducer Targeted for 2014 and 2015 VANCOUVER , May 8, 2014 ...
Devices, Cardiology, Personnel
Neovasc, Neovasc Reducer, Tiara

MediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica

周四, 05/08/2014 - 13:20
YAVNE, Israel, May 8, 2014 -- (Healthcare Sales & Marketing Network) -- MediWound Ltd. (MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced today the signi...
Biopharmaceuticals, Wound Care, Distribution
MediWound, Genfa Medica, NexoBrid

Timothy Maloney appointed President of Novartis Pharmaceuticals Canada Inc.

周四, 05/08/2014 - 13:15
DORVAL, QC , May 8, 2014 (Healthcare Sales & Marketing Network) - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Timothy Maloney has been appointed Country Head and President, effective April 1, 2014 . Mr. Maloney brings with him 28 years...
Biopharmaceuticals, Personnel
Novartis Pharmaceuticals Canada

Acura Pharmaceuticals Announces Settlement of Patent Litigation With Ranbaxy Inc.

周四, 05/08/2014 - 13:05
PALATINE, IL--(Healthcare Sales & Marketing Network) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that it has entered into a Settlement...
Biopharmaceuticals, Generics, Litigation
Acura Pharmaceuticals, Ranbaxy, oxycodone

Elekta announces changes to its Executive Management team

周四, 05/08/2014 - 12:59
Elekta announced today that it has appointed Åsa Hedin as Executive Vice President (EVP) Corporate Strategy, assuming responsibility for Strategy, Marketing and Education & Training. Elekta also announced that Maurits Wolleswinkel has been appoint...
Devices, Neurosurgery, Oncology, Personnel
Elekta

The BD MAX(TM) Enteric Bacterial Panel Receives FDA Clearance to Detect the Most Common Causes of Bacterial Gastroenteritis

周三, 05/07/2014 - 15:37
SPARKS, Md., May 7, 2014 -- (Healthcare Sales & Marketing Network) -- BD Diagnostics, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (BDX), announced today the availability of the FDA-cleared BD MAX™ Enteric Bact...
Diagnostics, FDA
BD , BD Diagnostics, BD MAX, Enteric Bacterial Panel

Elekta announces strategic partnership with the Centre hospitalier de l'Universite de Montreal

周三, 05/07/2014 - 15:34
Cancer treatment equipment and oncology information system to increase efficiency and standard of treatment MONTREAL , May 7, 2014 (Healthcare Sales & Marketing Network) - Elekta has signed an agreement to provide the Centre hospitalier de l'Universite...
Devices, Oncology
Elekta, Elekta Infinity, MOSAIQ, linear accelerator, radiotherapy

FDA Approves BIOTRONIK Entovis Pacemaker System with ProMRI(R) Technology

周三, 05/07/2014 - 15:29
First MR Conditional Pacemaker Portfolio in the U.S. with Single- and Dual-Chamber Pacemakers LAKE OSWEGO, Ore.--(Healthcare Sales & Marketing Network)--BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food a...
Devices, Cardiology, FDA
BIOTRONIK, Entovis, Pacemaker

Myriad and UnitedHealthcare Sign Three-Year Agreement Making myRisk(TM) Hereditary Cancer Test Available to United Members

周二, 05/06/2014 - 13:43
SALT LAKE CITY, May 6, 2014 -- (Healthcare Sales & Marketing Network) -- Myriad Genetics, Inc. (MYGN) announced today that it has signed a three-year contract with UnitedHealthcare. The contract provides UnitedHealthcare with access for BRCA testing and th...
Diagnostics, Oncology
Myriad Genetics, myRisk Hereditary Cancer test, BRCA, breast cancer

Boston Scientific Joins Optum Labs as Founding Medical Device Partner

周二, 05/06/2014 - 13:38
Global medical solutions innovator seeks to pioneer new research into effective treatments for heart failure and related cardiac conditions NATICK, Mass., May 6, 2014 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) has ...
Devices, Cardiology
Boston Scientific, Optum Labs, heart failure

Surgeon Performs First Mazor Robotics Renaissance(R) Spine Surgery with Full Integration of Intraoperative Imaging System

周二, 05/06/2014 - 13:32
ORLANDO, Fla.,--(Healthcare Sales & Marketing Network)--Dr. Dimitry Dzukaev performed a series of 10 successful spine procedures utilizing Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) Renaissance Guidance System with full integration of an intraoperative im...
Devices, Orthopaedic, Neurosurgery
Mazor Robotics, Renaissance System, robotic surgery

FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia

周二, 05/06/2014 - 12:34
WILMINGTON, Del., May 6, 2014 -- (Healthcare Sales & Marketing Network) -- AstraZeneca (AZN) today announced the US Food and Drug Administration (FDA) approved EPANOVA® (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in ...
Biopharmaceuticals, FDA
AstraZeneca, EPANOVA, omega-3-carboxylic, hypertriglyceridemia

Aeterna Zentaris Selects Charleston, S.C. as New Location for its North American Business and Global Commercial Operations

周一, 05/05/2014 - 12:55
QUÉBEC CITY, May 5, 2014 -- (Healthcare Sales & Marketing Network) - Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) (the "Company"), a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology, toda...
Biopharmaceuticals
Aeterna Zentaris

SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Officer

周一, 05/05/2014 - 12:52
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--SAGE Therapeutics (SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the appointment of Thomas D. ...
Biopharmaceuticals, Personnel
SAGE Therapeutics

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong